Phase 2 Hepatitis B Trial, Recruiting NCT07364448 Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Condition: Hepatitis B
Back to Hepatitis B

Phase 2 Hepatitis B Trial, Recruiting

NCT07364448
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older, of any gender.
  • You have been assessed by a doctor as having chronic hepatitis B with liver scarring (fibrosis), OR fatty liver disease with fibrosis, including early-stage cirrhosis that is still "compensated" (meaning the liver is still functioning), confirmed by biopsy, imaging, or blood tests meeting specific thresholds.
  • Your liver scarring has been confirmed by at least one of the following: a tissue biopsy showing moderate-to-advanced fibrosis (stage F2 or higher); an endoscopy showing enlarged veins in the oesophagus or stomach caused by cirrhosis; or specific liver scan or blood test results above certain levels depending on your condition (confirm exact values with trial site).
  • You are willing and able to use effective contraception throughout the trial and for at least 6 months after the last dose — this applies to both men and women of childbearing potential.
  • If you are a woman, you must not be pregnant or breastfeeding, and must either be past childbearing age/have had certain procedures, or agree to use reliable contraception and not donate eggs during the trial period.
  • You are willing to take part, able to follow the trial's requirements, and can understand and sign a consent form.

Who may not be able to join:

  • Your blood tests at the start of the trial show that certain liver function markers (bilirubin or liver enzyme ALT) are significantly above the normal range (confirm specific levels with trial site).
  • Your blood test shows a protein called alpha-fetoprotein (AFP) is above 20 μg/L at the start of the trial, which can sometimes indicate liver problems or cancer.
  • Your blood platelet count is too low, or your blood clotting time (INR) is too high at the start of the trial, suggesting the liver is not functioning well enough (confirm exact values with trial site).
  • You have been diagnosed with, or currently have, advanced (decompensated) cirrhosis, or scans show suspicious lumps or growths in the liver larger than 10mm, or anything that might suggest cancer.
  • You have been diagnosed with any other type of cancer in the past 5 years — although some early-stage or fully treated skin cancers, bladder cancer, cervical pre-cancer, or localised prostate cancer may be exceptions (confirm with trial site).
  • You have used a type of medication called interferon within the 3 months before joining the trial.
  • You have a serious ongoing condition affecting the heart, lungs, kidneys, hormones, nervous system, digestive system, blood, or a significant mental health condition.
  • You plan to take part in another interventional clinical trial at the same time as this one.
  • You have taken part in any other clinical trial within the 3 months before joining.
  • You are currently pregnant or breastfeeding.
  • The trial doctor considers there to be any other reason you would not be suitable to join (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-13501209210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Registry
ClinicalTrials.gov
Start date
12 March 2026
Est. completion
30 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Any adverse events occurring in study participants following drug administration.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov